More recently, the addition of lymphocyte-activation gene 3 (LAG-3) inhibitors, such as relatlimab, in combination with PD-1 blockade, has demonstrated further improvement in clinical outcomes, enhancing effector T-cell activity while circumventing tumour immune escape. The gene discussed is LAG3; the disease is neoplasm.